Stay updated on IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page’s interface release/version stamp is updated from **Revision: v3.5.2** to **Revision: v3.5.3**, indicating a software/template update without changing the underlying trial information.SummaryDifference0.1%

- Check12 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check41 days agoChange DetectedRevision: v3.5.0 added; v3.4.3 removed.SummaryDifference0.1%

- Check49 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check77 days agoChange DetectedAn addition of Revision: v3.4.2 and a deletion of Revision: v3.4.1 were made in the page's revision history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; there are no changes to study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.